Payment overview · 2025
General Payments
$986.13
50 reported records · 16 companies
Healthcare provider profile · identity verified
Bassem Zraik, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLEVELAND, OH · NPI 1548542491
Verified facts
What the public records show
CMS Open Payments records show Bassem Zraik, MD received $986.13 in general payments during 2025 across 50 reported records.
Vanda Pharmaceuticals Inc. accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Kerendia, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 532 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 532 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $251.18 | 25.5% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $149.49 | 15.2% | 10 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $90.76 | 9.2% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $76.58 | 7.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $67.38 | 6.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $60.79 | 6.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.58 | 4.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $44.37 | 4.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.40 | 3.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $36.68 | 3.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.89 | 3.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.05 | 2.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.92 | 1.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.55 | 1.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.38 | 1.7% | 1 | 2025 |
| TMS NeuroHealth Centers Inc. | Unresolved — no canonical attribution shown | $13.13 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $943.63 | 49 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $251.18 | 14 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $168.86 | 9 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $90.76 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $76.58 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $60.79 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $59.21 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $59.21 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $57.21 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.58 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $44.37 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $36.68 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $33.07 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.98 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $30.89 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $30.89 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $30.89 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.15 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| TMS NeuroHealth Centers Inc. Normalized: tms neurohealth centers inc |
Device | TMS NeuroHealth Centers Inc. | $13.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 532 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 36 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | 18 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
532 | 70 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
84 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
532 | 70 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 652 | 164 |
| Eliquis | Apixaban | 532 | 70 |
| Furosemide | Furosemide | 375 | 86 |
| Gabapentin | Gabapentin | 373 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 368 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 305 | 75 |
| Trazodone Hcl | Trazodone Hcl | 274 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 263 | 72 |
| Lisinopril | Lisinopril | 242 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 231 | 53 |
| Mirtazapine | Mirtazapine | 223 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 209 | 51 |
| Sertraline Hcl | Sertraline Hcl | 185 | 49 |
| Donepezil Hcl | Donepezil Hcl | 173 | 35 |
| Losartan Potassium | Losartan Potassium | 171 | 42 |
| Buspirone Hcl | Buspirone Hcl | 154 | 27 |
| Memantine Hcl | Memantine Hcl | 154 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 152 | 31 |
| Carvedilol | Carvedilol | 150 | 42 |
| Potassium Chloride | Potassium Chloride | 147 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 144 | 16 |
| Metformin Hcl | Metformin Hcl | 139 | 39 |
| Omeprazole | Omeprazole | 136 | 32 |
| Divalproex Sodium | Divalproex Sodium | 134 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 45 |
| Baclofen | Baclofen | 127 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 117 | 26 |
| Finasteride | Finasteride | 114 | 24 |
| Sevelamer Carbonate | Sevelamer Carbonate | 109 | suppressed |
| Simvastatin | Simvastatin | 105 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 21 |
| Midodrine Hcl | Midodrine Hcl | 87 | 22 |
| Trulicity | Dulaglutide | 84 | suppressed |
| Levetiracetam | Levetiracetam | 79 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 77 | 33 |
| Allopurinol | Allopurinol | 76 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 30 |
| Warfarin Sodium | Warfarin Sodium | 71 | 13 |
| Spironolactone | Spironolactone | 70 | 20 |
| Humalog Kwikpen U-100 | Insulin Lispro | 64 | 19 |
| Januvia | Sitagliptin Phosphate | 64 | suppressed |
| Risperidone | Risperidone | 63 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 38 |
| Xarelto | Rivaroxaban | 62 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 19 |
| Myrbetriq | Mirabegron | 59 | suppressed |
| Prednisone | Prednisone | 58 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | suppressed |
| Latanoprost | Latanoprost | 56 | 17 |
| Famotidine | Famotidine | 55 | 17 |
| Bupropion Xl | Bupropion Hcl | 54 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 53 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 25 |
| Cephalexin | Cephalexin | 48 | 24 |
| Enoxaparin Sodium | Enoxaparin Sodium | 48 | suppressed |
| Sucralfate | Sucralfate | 48 | 13 |
| Loperamide | Loperamide Hcl | 47 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 34 |
| Torsemide | Torsemide | 45 | 18 |
| Atenolol | Atenolol | 43 | suppressed |
| Carbamazepine | Carbamazepine | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 33 |
| Nystatin | Nystatin | 43 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 42 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Ibuprofen | Ibuprofen | 37 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 16 |
| Jardiance | Empagliflozin | 36 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 15 |
| Benztropine Mesylate | Benztropine Mesylate | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Jantoven | Warfarin Sodium | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Gamastan | Immune Globul G (Igg)/Glycine | 28 | suppressed |
| Lidocaine | Lidocaine | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 23 |
| Pregabalin | Pregabalin | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 18 |
| Calcitriol | Calcitriol | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 23 |
| Flecainide Acetate | Flecainide Acetate | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | 14 |
| Admelog | Insulin Lispro | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 13 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Timolol Maleate | Timolol Maleate | 22 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 22 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 21 | 11 |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 21 | 15 |
| Digoxin | Digoxin | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | 14 |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | 11 |
| Ozempic | Semaglutide | 20 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 14 |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | 11 |
| Budesonide | Budesonide | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Phenytoin | Phenytoin | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | 16 |
| Zonisamide | Zonisamide | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Perforomist | Formoterol Fumarate | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Acetic Acid | Acetic Acid | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $986.13 · 50 records | Vanda Pharmaceuticals Inc. | ABRYSVO, AFREZZA, AIRSUPRA, AMYVID, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FANAPT, FARXIGA, HETLIOZ, JARDIANCE, KISUNLA, Kerendia, Korlym, MOUNJARO, Ozempic, PREVNAR 20, REXULTI, TMS NeuroHealth Centers Inc., VRAYLAR, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error